$13.52
▼ -0.0% Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting
Overview
52-week range
$5.69
$13
100% of range
Avg surprise (last 2)
+10.0%
Avg reaction (last 1)
-26.9%
0% positive
Latest IV / EM
55%
EM ±13.0% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $0.55 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $0.61 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $0.94 | $0.89 | +5.6% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $0.95 | $0.83 | +14.5% | — | -26.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $1.38 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.75 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.78 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.23 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.95 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | $0.85 | $0.94 | -9.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.46B | — | $1.60B | $1.59B | $1.51B | — | $1.58B | $1.61B |
| Cost of revenue | $677M | — | $745M | $720M | $672M | — | $659M | $668M |
| Gross profit | $783M | — | $857M | $874M | $841M | — | $923M | $939M |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $146M | — | $160M | $145M | $87M | — | $359M | $195M |
| EPS (diluted) | $0.55 | — | $0.61 | $0.56 | $0.33 | — | $1.38 | $0.75 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.12B | $574M | $672M | $599M | $547M | $675M | $763M | $704M |
| Inventory | $1.37B | $1.41B | $1.49B | $1.45B | $1.36B | $1.32B | $1.38B | $1.29B |
| Total current assets | $4.93B | $4.35B | $4.70B | $4.62B | $4.37B | $4.35B | $4.76B | $4.51B |
| Total assets | $13.00B | $12.87B | $13.55B | $13.50B | $13.16B | $13.10B | $12.75B | $12.15B |
| Long-term debt | $8.55B | $8.63B | $8.78B | $8.78B | $8.94B | $8.86B | $8.74B | $8.65B |
| Total liabilities | $12.09B | $12.12B | $12.65B | $12.77B | $12.61B | $12.63B | $12.26B | $12.01B |
| Total equity | $903M | $752M | $906M | $733M | $542M | $472M | $493M | $144M |